BETPELMY

Dead / Abandoned — Abandoned — after inter partes decision (as of 14 Feb 2025)

What this means for you

This application is over — abandoned 14 Feb 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.

Record

Serial number
97786672
Mark type
Stylized text
Filed
08 Feb 2023
Published for opposition
11 Jun 2024
Abandoned
14 Feb 2025
Attorney of record
KEITH TOMS

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, trombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways

Owner

Prosecution history

  • 14 Feb 2025 — ABANDONMENT NOTICE E-MAILED - INTER PARTES DECISION
  • 14 Feb 2025 — ABANDONMENT - AFTER INTER PARTES DECISION
  • 14 Feb 2025 — OPPOSITION TERMINATED NO. 999999
  • 14 Feb 2025 — OPPOSITION DISMISSED NO. 999999
  • 10 Aug 2024 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
  • 05 Aug 2024 — OPPOSITION INSTITUTED NO. 999999
  • 08 Jul 2024 — EXTENSION OF TIME TO OPPOSE RECEIVED
  • 11 Jun 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 11 Jun 2024 — PUBLISHED FOR OPPOSITION
  • 22 May 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 08 May 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 08 May 2024 — EXAMINER'S AMENDMENT ENTERED
  • 08 May 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
  • 08 May 2024 — EXAMINERS AMENDMENT E-MAILED
  • 08 May 2024 — EXAMINERS AMENDMENT -WRITTEN

View this trademark record on Marksy